MedTrace Logo

Ketamine For Suicidal Ideation

NCT01507181 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2017-02-08

Study results available
· View outcomes & findings →

Summary

This study will examine the effects of Intravenous (IV) ketamine both in an outpatient population and with subjects on the inpatient unit with suicidal ideation (SI).

Conditions

Interventions

DRUG

Ketamine

single dose IV ketamine, .5mg/kg infused over 40 minutes

DRUG

Midazolam

single dose IV midazolam, .45mg/kg infused over 40 minutes

Sponsors & Collaborators

  • James Murrough

    lead OTHER

Principal Investigators

  • James Murrough, MD · Icahn School of Medicine at Mount Sinai

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-01-31
Primary Completion
2014-09-30
Completion
2014-09-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01507181 on ClinicalTrials.gov